BRIEF-Johnson & Johnson Says Talvey,Tecvayli Shows Deep,Durable Responses In Heavily Pretreated Multiple Myeloma Patients With Extramedullary DiseaseJune 15 (Reuters) - Johnson & Johnson JNJ.N:
INVESTIGATIONAL COMBINATION OF FIRST-IN-CLASS BISPECIFICS TALVEY® AND TECVAYLI® SHOWS DEEP AND DURABLE RESPONSES IN HEAVILY PRETREATED MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE
JOHNSON & JOHNSON - PHASE 2 STUDY SHOWS 78.9% OVERALL RESPONSE RATE
JOHNSON & JOHNSON - NOVEL APPROACH SHOWS POTENTIAL IN EXTRAMEDULLARY DISEASE PATIENTS
JOHNSON & JOHNSON - COMBINATION THERAPY ACHIEVES 78.9% ORR, 54.4% COMPLETE RESPONSE
JOHNSON & JOHNSON - 61% OF PATIENTS PROGRESSION FREE AND ALIVE AT ONE YEAR
JOHNSON & JOHNSON - 64.1% MAINTAIN RESPONSE, 74.5% ALIVE AT ONE YEAR
Source text: ID:nPn476M5Xa
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments